| Year |
Citation |
Score |
| 2020 |
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, et al. Hormonal modulation of ESR1 mutant metastasis. Oncogene. PMID 33323970 DOI: 10.1038/s41388-020-01563-x |
0.371 |
|
| 2019 |
De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, et al. Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31653641 DOI: 10.1158/1078-0432.Ccr-19-1402 |
0.423 |
|
| 2019 |
Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, et al. . Molecular Cancer Research : McR. PMID 31420371 DOI: 10.1158/1541-7786.Mcr-19-0756 |
0.423 |
|
| 2017 |
Fu X, Pereira R, Zhao D, Jung S, Jeselsohn R, Creighton C, Shea M, Nardone A, Angelis C, Tsimelzon A, Wang T, Gutierrez C, Huang S, Edwards D, Rimawi M, et al. Abstract PD2-04: FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd2-04 |
0.427 |
|
| 2017 |
Gu G, Tian L, Gao M, Rechoum Y, Gelsomino L, Dustin D, Corona-Rodriguez A, Beyer AR, Tsimelzon A, Zhang X, Ando S, Fuqua S. Abstract 22: The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis Cancer Research. 78: 22-22. DOI: 10.1158/1538-7445.Am2018-22 |
0.46 |
|
| 2017 |
Mazumdar A, Hill J, Zhang Y, Bollu LR, Tsimelzon A, Chang J, Mills G, Brown P. Abstract 5525: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing CDK phosphorylation Cancer Research. 77: 5525-5525. DOI: 10.1158/1538-7445.Am2017-5525 |
0.48 |
|
| 2016 |
Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, ... Tsimelzon A, et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 113: E6600-E6609. PMID 27791031 DOI: 10.1073/Pnas.1612835113 |
0.475 |
|
| 2016 |
Ochsner SA, Tsimelzon A, Dong J, Coarfa C, McKenna NJ. Research Resource: A reference transcriptome for constitutive androstane receptor and pregnane X receptor xenobiotic signaling. Molecular Endocrinology (Baltimore, Md.). me20161095. PMID 27409825 DOI: 10.1210/Me.2016-1095 |
0.317 |
|
| 2016 |
Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment. PMID 27393618 DOI: 10.1007/S10549-016-3892-Y |
0.527 |
|
| 2016 |
Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, Andò S, Fuqua SA. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Research and Treatment. PMID 27178332 DOI: 10.1007/S10549-016-3829-5 |
0.433 |
|
| 2016 |
den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Research. PMID 26921331 DOI: 10.1158/0008-5472.Can-14-0673 |
0.537 |
|
| 2016 |
Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PH. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. PMID 26894864 DOI: 10.18632/Oncotarget.7437 |
0.458 |
|
| 2016 |
Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BW. HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Research. 76: 1463-75. PMID 26833126 DOI: 10.1158/0008-5472.Can-15-2383 |
0.467 |
|
| 2016 |
Elsarraj H, Yan H, Knapp J, Tsimelzon A, Huang S, Godwin A, Hilsenbeck S, Edwards D, Behbod F. Abstract B01: B cell lymphoma 9 mediates a cross talk between the canonical Wnt and EGFR signaling in breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B01 |
0.511 |
|
| 2016 |
Shepherd J, Mazumdar A, Tsimelzon A, Hilsenbeck SG, Brown PH. Abstract 2913: The SOX11 transcription factor is critical for basal-like breast cancer growth and migration and is associated with poor survival Cancer Research. 76: 2913-2913. DOI: 10.1158/1538-7445.Am2016-2913 |
0.514 |
|
| 2015 |
Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. Breast Cancer Research and Treatment. PMID 26487496 DOI: 10.1007/S10549-015-3609-7 |
0.398 |
|
| 2015 |
Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discovery. 5: 520-33. PMID 25735774 DOI: 10.1158/2159-8290.Cd-14-1101 |
0.411 |
|
| 2015 |
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1688-98. PMID 25208879 DOI: 10.1158/1078-0432.Ccr-14-0432 |
0.458 |
|
| 2014 |
Mazumdar A, Poage G, Hill J, Zhang Y, Tsimelzon A, Chang J, Mills G, Brown P. Abstract 5279: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing cell cycle Cancer Research. 74: 5279-5279. DOI: 10.1158/1538-7445.Am2014-5279 |
0.522 |
|
| 2014 |
Batra N, Speers C, Uray I, Mazumdar A, Tsimelzon A, Hilsenbeck S, Mills G, Brown P. Abstract 3299: Maternal embryonic leucine zipper kinase is critical for the growth and migration of triple negative breast cancer cells Cancer Research. 74: 3299-3299. DOI: 10.1158/1538-7445.Am2014-3299 |
0.503 |
|
| 2013 |
Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG, Fuqua SA. Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment. PMID 24077732 DOI: 10.1007/S10549-013-2709-5 |
0.514 |
|
| 2013 |
Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, ... ... Tsimelzon A, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Research. 73: 4885-97. PMID 23737486 DOI: 10.1158/0008-5472.Can-12-4081 |
0.443 |
|
| 2013 |
Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Research. 73: 3470-80. PMID 23633491 DOI: 10.1158/0008-5472.Can-12-4524-T |
0.323 |
|
| 2013 |
Mazumdar A, Hollander PD, Poage G, Hill J, Zhang Y, Tsimelzon A, Hilsenbeck S, Chang J, Mills G, Brown PH. Abstract 856: High expression of DUSP4 in ER-negative breast cancer cells suppresses growth and invasion. Cancer Research. 73: 856-856. DOI: 10.1158/1538-7445.Am2013-856 |
0.517 |
|
| 2013 |
Shepherd J, Uray IP, Mazumdar A, Tsimelzon A, Hilsenbeck SG, Brown PH. Abstract 3124: Identification of transcription factors critical for the growth of basal-like breast cancer. Cancer Research. 73: 3124-3124. DOI: 10.1158/1538-7445.Am2013-3124 |
0.473 |
|
| 2013 |
Burstein MD, Tsimelzon A, Covington KR, Fuqua SA, Chang JC, Hilsenbeck SG, Osborne CK, Mills GB, Lau CC, Brown PH. Abstract 1996: Identification of four subgroups of Triple Negative Breast Cancer (TNBC) by genomic profiling. Cancer Research. 73: 1996-1996. DOI: 10.1158/1538-7445.Am2013-1996 |
0.451 |
|
| 2013 |
Burstein, Tsimelzon A, Hilsenbeck S, Fuqua S, Chang J, Osborne C, Mills G, Brown P, Lau C. Abstract P4-06-01: Expression and DNA copy number profiling suggest novel therapeutic approaches for triple negative breast cancer subtypes Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-06-01 |
0.448 |
|
| 2012 |
Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC. A gene transcription signature of obesity in breast cancer. Breast Cancer Research and Treatment. 132: 993-1000. PMID 21750966 DOI: 10.1007/S10549-011-1595-Y |
0.4 |
|
| 2012 |
Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Research and Treatment. 132: 61-73. PMID 21541704 DOI: 10.1007/S10549-011-1540-0 |
0.476 |
|
| 2012 |
Hartman ZC, Tsimelzon A, Uray IP, Hill J, Zhang Y, Mazumdar A, Hilsenbeck SG, Chang J, Mills GB, Brown PH. Abstract 4862: Autocrine secreted IL-6 and IL-8 play critical and non-redundant roles in basal-like breast cancer cell transformation and growthin vitroandin vivo Cancer Research. 72: 4862-4862. DOI: 10.1158/1538-7445.Am2012-4862 |
0.455 |
|
| 2012 |
Mazumdar A, Hollander PD, Tsimelzon A, Hilsenbeck S, Chang J, Mills G, Brown P. Abstract 2857: Induced expression of DUSP4 and PPM1A in ER-negative breast cancer cells suppresses proliferation and invasion Cancer Research. 72: 2857-2857. DOI: 10.1158/1538-7445.Am2012-2857 |
0.522 |
|
| 2012 |
Hollander Pd, Mazumdar A, Tsimelzon A, Hilsenbeck S, Chang J, Mills G, Brown P. Abstract 2853: Discovery of phosphatases that regulate growth and tumorigenicity of ER-negative breast cancers Cancer Research. 72: 2853-2853. DOI: 10.1158/1538-7445.Am2012-2853 |
0.52 |
|
| 2011 |
Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A, Boumendjel A, Albain K, Miele L, Weiss H, Barone I, et al. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6510-21. PMID 21878538 DOI: 10.1158/1078-0432.Ccr-11-1403 |
0.494 |
|
| 2011 |
Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Research and Treatment. 129: 819-27. PMID 21792626 DOI: 10.1007/S10549-011-1679-8 |
0.428 |
|
| 2011 |
Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. Journal of the National Cancer Institute. 103: 538-52. PMID 21447808 DOI: 10.1093/Jnci/Djr058 |
0.415 |
|
| 2011 |
Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2314-27. PMID 21177763 DOI: 10.1158/1078-0432.Ccr-10-1903 |
0.434 |
|
| 2011 |
Hartman ZC, Tsimelzon A, Hill J, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills G, Brown PH. Abstract A42: Autocrine-produced IL-6 and IL-8 are essential for the growth and maintenance of the transformed phenotype of basal-like breast cancer cells Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-A42 |
0.505 |
|
| 2011 |
Covington KR, Gu G, Tsimelzon A, Hilsenbeck S, Brown P, Change J, Osborne CK, Xu J, O'Malley B, Mangelsdorf D, Minna J, Fuqua S. Abstract 2296: Identification of novel nuclear receptor targets in estrogen receptor negative breast cancer Cancer Research. 71: 2296-2296. DOI: 10.1158/1538-7445.Am2011-2296 |
0.441 |
|
| 2011 |
Mazumdar A, Speers C, Wang C, Tsimelzon A, Hilsenbeck S, Brown P. Abstract 1665: Targeting phosphatases for the treatment of ER-negative breast cancer Cancer Research. 71: 1665-1665. DOI: 10.1158/1538-7445.Am2011-1665 |
0.46 |
|
| 2011 |
Wheatley K, Speers C, Tsimelzon A, Sexton K, Hilsenbeck S, Chang J, Brown P. Abstract 1664: Maternal embryonic leucine aipper kinase (MELK) is a critical regulator of proliferation and is independently prognostic in estrogen receptor-negative breast cancer Cancer Research. 71: 1664-1664. DOI: 10.1158/1538-7445.Am2011-1664 |
0.526 |
|
| 2011 |
Shepherd J, Mazumdar A, Tsimelzon A, Hilsenbeck S, Brown P. PD03-03: Identification of Transcription Factors Critical for the Growth of Basal Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd03-03 |
0.501 |
|
| 2011 |
Zhang X, Dobrolecki L, Lai Q, Landis, Wong H, Tsimelzon A, Claerhout S, Contreras A, Gutierrez C, Huang J, Wu M, Pavlick A, Froehlich A, Hilsenbeck S, Mills G, et al. P5-21-01: A Renewable Tissue Resource of Phenotypically Stable Human Breast Cancer Xenografts for Preclinical Studies. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-21-01 |
0.437 |
|
| 2011 |
Healy N, Creighton C, Fu X, Tsimelzon A, Hilsenbeck S, Miller N, Kerin M, Osborne C, Schiff R. P3-03-05: Identification of miRNAs and Their Associated Target Genes Involved in Endocrine Resistance in Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-03-05 |
0.362 |
|
| 2010 |
Foulds CE, Tsimelzon A, Long W, Le A, Tsai SY, Tsai MJ, O'Malley BW. Research resource: expression profiling reveals unexpected targets and functions of the human steroid receptor RNA activator (SRA) gene. Molecular Endocrinology (Baltimore, Md.). 24: 1090-105. PMID 20219889 DOI: 10.1210/Me.2009-0427 |
0.334 |
|
| 2010 |
Hammerich-Hille S, Kaipparettu BA, Tsimelzon A, Creighton CJ, Jiang S, Polo JM, Melnick A, Meyer R, Oesterreich S. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. The Journal of Biological Chemistry. 285: 3608-16. PMID 19901029 DOI: 10.1074/Jbc.M109.066431 |
0.407 |
|
| 2010 |
De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Research and Treatment. 121: 1-11. PMID 19533338 DOI: 10.1007/S10549-009-0436-8 |
0.491 |
|
| 2010 |
Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Research and Treatment. 119: 305-14. PMID 19241157 DOI: 10.1007/s10549-009-0350-0 |
0.465 |
|
| 2010 |
Wang Y, Litzenburger B, Kuiatse I, Dearth RK, Casa AJ, Tsimelzon A, Hilsenbeck SG, Li J, Hennessey BT, Mills GB, Rimawi MF, Lee AV. Abstract 4133: Comparative gene expression and proteomic analysis of IGF-I and insulin signaling in a large panel of breast cancer cell lines Cancer Research. 70: 4133-4133. DOI: 10.1158/1538-7445.Am10-4133 |
0.386 |
|
| 2009 |
Selever J, Barone I, Lewis MT, Corona-Rodriguez A, Tsimelzon A, Di Pietro A, Boumemdjel A, Fuqua S. Effect of estrogen receptor-positive progenitor cells on a tamoxifen resistance phenotype in breast cancer cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1042. PMID 27961120 DOI: 10.1200/Jco.2009.27.15_Suppl.1042 |
0.505 |
|
| 2009 |
Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6327-40. PMID 19808870 DOI: 10.1158/1078-0432.Ccr-09-1107 |
0.507 |
|
| 2009 |
Rodriguez A, Makris A, Harrison M, Ostler P, Froehlich A, Pavlick A, Wong H, Tsimelzon A, Sexton K, Hilsenbeck S, Lewis M, Rimawi M, Osborne C, Chang J. BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer. Cancer Research. 69: 6039. DOI: 10.1158/0008-5472.Sabcs-6039 |
0.496 |
|
| 2009 |
Covington K, Barone I, Cui Y, Tsimelzon A, Rodriguez A, Wang T, Fuqua S. MTA2 is a metastasis promoter in breast cancer cells. Cancer Research. 69: 2047. DOI: 10.1158/0008-5472.Sabcs-2047 |
0.493 |
|
| 2009 |
Covington K, Tsimelzon A, Fuqua S. MTA2 Enhances Breast Cancer Metastasis by Regulating the Rho Signaling Pathway. Cancer Research. 69: 6143-6143. DOI: 10.1158/0008-5472.Sabcs-09-6143 |
0.479 |
|
| 2009 |
Barone I, Beyer A, Covington K, Tsimelzon A, Ando S, Fuqua S. Phosphorylation of the Mutant K303R Estrogen Receptor α at Serine 305 Impacts Aromatase Inhibitor Sensitivity. Cancer Research. 69: 5053-5053. DOI: 10.1158/0008-5472.Sabcs-09-5053 |
0.437 |
|
| 2009 |
Wang Y, Litzenburger B, Kuiatse I, Dearth R, Casa A, Tsimelzon A, Hilsenbeck S, Li J, Hennessey B, Mills G, Lee A. Expression and Activity of Both IGF and Insulin Signaling Pathways in a Large Panel of Breast Cancer Cell Lines. Cancer Research. 69: 4168-4168. DOI: 10.1158/0008-5472.Sabcs-09-4168 |
0.437 |
|
| 2009 |
Litzenburger B, Tsimelzon A, Hilsenbeck S, Creighton C, Carboni J, Gottardis M, Wicha M, Chang J, Lewis M, Lee A. High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines Correlates with Sensitivity to IGF-IR Inhibitor BMS-754807 in This Subtype of Human Breast Cancer. Cancer Research. 69: 1132-1132. DOI: 10.1158/0008-5472.Sabcs-09-1132 |
0.503 |
|
| 2009 |
Casa A, Malik S, Lazard Z, Kuiatse I, Tsimelzon A, Creighton C, Hilsenbeck S, Lee A, Oesterreich S. Estrogen and IGF-I Independently Down-Regulate Critical Repressors of Breast Cancer Growth. Cancer Research. 69: 1126-1126. DOI: 10.1158/0008-5472.Sabcs-09-1126 |
0.462 |
|
| 2008 |
Yang W, Sahin AA, Wong H, Tsimelzon A, Hess K, Karadag N, Cairo M, Meric F, Arun B, Chang JC. Molecular portraits of mammographic breast density in normal breast tissue. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 22227. PMID 27950301 DOI: 10.1200/Jco.2008.26.15_Suppl.22227 |
0.428 |
|
| 2008 |
Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Research. 68: 7493-501. PMID 18794137 DOI: 10.1158/0008-5472.Can-08-1404 |
0.489 |
|
| 2008 |
Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4078-85. PMID 18757322 DOI: 10.1200/Jco.2007.13.4429 |
0.511 |
|
| 2008 |
Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Research. 68: 4674-82. PMID 18559513 DOI: 10.1158/0008-5472.Can-07-6353 |
0.359 |
|
| 2008 |
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research. 68: 826-33. PMID 18245484 DOI: 10.1158/0008-5472.Can-07-2707 |
0.427 |
|
| 2008 |
Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 370-8. PMID 18223211 DOI: 10.1158/1078-0432.Ccr-07-1127 |
0.399 |
|
| 2007 |
Redell MS, Tsimelzon A, Hilsenbeck SG, Tweardy DJ. Conditional overexpression of Stat3alpha in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. Journal of Leukocyte Biology. 82: 975-85. PMID 17634277 DOI: 10.1189/Jlb.1206766 |
0.326 |
|
| 2007 |
Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, Allred DC. Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. The American Journal of Pathology. 171: 252-62. PMID 17591970 DOI: 10.2353/Ajpath.2007.061010 |
0.507 |
|
| 2006 |
Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5047-54. PMID 16951220 DOI: 10.1158/1078-0432.Ccr-05-2248 |
0.464 |
|
| 2006 |
Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Research. 66: 5950-9. PMID 16740736 DOI: 10.1158/0008-5472.Can-05-3243 |
0.435 |
|
| 2006 |
Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Research and Treatment. 95: 229-33. PMID 16322899 DOI: 10.1007/S10549-005-9009-7 |
0.39 |
|
| 2006 |
Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM. Transcriptional profiling of mammary gland side population cells. Stem Cells (Dayton, Ohio). 24: 1065-74. PMID 16282442 DOI: 10.1634/Stemcells.2005-0375 |
0.313 |
|
| 2006 |
Redell M, Tsimelzon A, Hilsenbeck SG, Tweardy DJ. Overexpression of Stat3α, but Not Statβ, in Myeloid Cells Results in Neutrophil Expansion through Reduced Apoptosis and Modulation of a Unique Set of Apoptosis Pathway Genes. Blood. 108: 1147-1147. DOI: 10.1182/Blood.V108.11.1147.1147 |
0.31 |
|
| 2005 |
Chang JC, Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Powles T, Wong H, Osborne CK, O'Connell P, Hilsenbeck S. Gene expression arrays for the prediction of response to doxorubicin and cyclophosphamide (AC) in human breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 543. PMID 27946432 DOI: 10.1200/Jco.2005.23.16_Suppl.543 |
0.453 |
|
| 2005 |
Tsimelzon A, Braslau R. Radical [n + 1] annulations with sulfur dioxide Journal of Organic Chemistry. 70: 10854-10859. PMID 16356008 DOI: 10.1021/Jo052035T |
0.586 |
|
| 2005 |
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1169-77. PMID 15718313 DOI: 10.1200/Jco.2005.03.156 |
0.461 |
|
| 2005 |
Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Research and Treatment. 89: 173-8. PMID 15692760 DOI: 10.1007/S10549-004-1722-0 |
0.374 |
|
| 2005 |
DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Molecular Endocrinology (Baltimore, Md.). 19: 362-78. PMID 15514030 DOI: 10.1210/Me.2004-0267 |
0.386 |
|
| 2005 |
Tsimelzon A, Deamer D, Braslau R. Synthesis and self-assembly of amphiphilic diblock copolymers using a fluorescently labeled N-alkoxyamine initiator Macromolecular Rapid Communications. 26: 1872-1877. DOI: 10.1002/Marc.200500608 |
0.567 |
|
| 2004 |
Braslau R, Tsimelzon A, Gewandter J. Novel methodology for the synthesis of N-alkoxyamines. Organic Letters. 6: 2233-5. PMID 15200328 DOI: 10.1021/Ol049271V |
0.576 |
|
| 2004 |
Braslau R, Tsimelzon A, Gewandter J. Novel methodology for the synthesis of n-alkoxyamines Organic Letters. 6: 2233-2235. DOI: 10.1021/ol049271v |
0.563 |
|
| 2003 |
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (London, England). 362: 362-9. PMID 12907009 DOI: 10.1016/S0140-6736(03)14023-8 |
0.461 |
|
| 2001 |
Li Z, Tsimelzon A, Immaneni A, Mohsin SK, Hilsenbeck SG, Clark GC, Fuqua SAW, Osborne CK, O'Connell P, Allred DC. Genetic alterations in the progression of non-invasive to invasive breast cancer Breast Cancer Research and Treatment. 69: 214. |
0.303 |
|
| Show low-probability matches. |